These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA). Ho PW; Leung CT; Liu H; Pang SY; Lam CS; Xian J; Li L; Kung MH; Ramsden DB; Ho SL Autophagy; 2020 Feb; 16(2):347-370. PubMed ID: 30983487 [TBL] [Abstract][Full Text] [Related]
5. LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease. Pang SY; Lo RCN; Ho PW; Liu HF; Chang EES; Leung CT; Malki Y; Choi ZY; Wong WY; Kung MH; Ramsden DB; Ho SL Transl Neurodegener; 2022 Jan; 11(1):5. PubMed ID: 35101134 [TBL] [Abstract][Full Text] [Related]
6. The Effect of p.G2019S Mutation in the Usenko TS; Timofeeva A; Beletskaia M; Basharova K; Baydakova G; Bezrukova A; Grunina M; Emelyanov A; Miliukhina I; Zakharova E; Pchelina S J Integr Neurosci; 2024 Jan; 23(1):16. PubMed ID: 38287861 [TBL] [Abstract][Full Text] [Related]
7. The GBA1 K198E Variant Is Associated with Suppression of Glucocerebrosidase Activity, Autophagy Impairment, Oxidative Stress, Mitochondrial Damage, and Apoptosis in Skin Fibroblasts. Perez-Abshana LP; Mendivil-Perez M; Jimenez-Del-Rio M; Velez-Pardo C Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273169 [TBL] [Abstract][Full Text] [Related]
8. LRRK2 impairs autophagy by mediating phosphorylation of leucyl-tRNA synthetase. Ho DH; Kim H; Nam D; Sim H; Kim J; Kim HG; Son I; Seol W Cell Biochem Funct; 2018 Dec; 36(8):431-442. PubMed ID: 30411383 [TBL] [Abstract][Full Text] [Related]
15. Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes. Lee CY; Menozzi E; Chau KY; Schapira AHV J Neurochem; 2021 Dec; 159(5):826-839. PubMed ID: 34618942 [TBL] [Abstract][Full Text] [Related]
16. In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity. Novello S; Mercatelli D; Albanese F; Domenicale C; Brugnoli A; D'Aversa E; Vantaggiato S; Dovero S; Murtaj V; Presotto L; Borgatti M; Shimshek DR; Bezard E; Moresco RM; Belloli S; Morari M Neurobiol Dis; 2022 Jan; 162():105579. PubMed ID: 34871735 [TBL] [Abstract][Full Text] [Related]
17. Upregulation of the p53-p21 pathway by G2019S LRRK2 contributes to the cellular senescence and accumulation of α-synuclein. Ho DH; Seol W; Son I Cell Cycle; 2019 Feb; 18(4):467-475. PubMed ID: 30712480 [TBL] [Abstract][Full Text] [Related]
18. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation. Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998 [TBL] [Abstract][Full Text] [Related]
19. Seventy-Two-Hour LRRK2 Kinase Activity Inhibition Increases Lysosomal GBA Expression in H4, a Human Neuroglioma Cell Line. Ruz C; Alcantud JL; Vives F; Arrebola F; Hardy J; Lewis PA; Manzoni C; Duran R Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805938 [TBL] [Abstract][Full Text] [Related]